Departments & Programs
In the Spotlight
Vandenborne’s MRI Technology A Potential Breakthrough for DMD Treatments
- In April at the American Academy of Neurology 70th Annual meeting, it was reported that the drug edasalonexent showed a remarkable impact on the treatment of Duchenne Muscular Dystrophy (DMD).
- Through the efforts of Dr. Krista Vandenborne, professor and chair of the Department of Physical Therapy, her MRI technology was able to collect data on young boys (3-7 years old) with DMD to measure the earliest changes in muscle — detecting effects of the disease before intervention is too late to take effect.
- Pharmaceutical companies are incorporating MRI techniques into their drug development programs.
- Any improvement in DMD pathology at this young age has the potential to improve the long-term disease trajectory and outlook of children with DMD.
